Tumor Suppressor p53: Biology, Signaling Pathways, and Therapeutic Targeting
By L. H. Borrero, W. El-Deiry. Biochimica et biophysica acta. Reviews on cancer, 2021
640 citations recorded by the source corpus.
TP53 is the most commonly mutated gene in human cancer with over 100,000 literature citations in PubMed. This is a heavily studied pathway in cancer biology and oncology with a history that dates back to 1979 when p53 was discovered. The p53 pathway is a complex cellular stress response network with multiple diverse inputs and downstream outputs relevant to its role as a tumor suppressor pathway. While inroads have been made in understanding the biology and signaling in the p53 pathway, the p53 family, transcriptional readouts, and effects of an array of mutants, the pathway remains challenging in the realm of clinical translation. While the role of mutant p53 as a prognostic factor is recognized, the therapeutic modulation of its wild-type or mutant activities remain a work-in-progress. This review covers current knowledge about the biology, signaling mechanisms in the p53 pathway and summarizes advances in therapeutic development.
Subfields: Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/73703a9f4b91cf22b9c2c8d6638e00cb716ae6ca
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Oncology
Citations in the corpus
- Cell cycle regulation: p53-p21-RB signaling (2022, background): “For instance, viral oncoproteins or overexpression of MDM2 cause p53 proteolysis [27, 28, 30].”